Drug Profile

HDT 201

Alternative Names: HDT 201

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HDT Bio; University of Washington
Developer HDT Bio
Class Antineoplastics; Antivirals; Immunotherapies; Proteins; RNA
Mechanism of Action DDX58 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical COVID 2019 infections
No development reported Cancer

Most Recent Events

28 Mar 2025 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
04 Oct 2023 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by HDT Bio
04 Oct 2023 HDT Bio plans a clinical trial in COVID-2019 infections

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com